Drug Trial Radar · NCT07104643
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)
Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Conditions
- mCRPC
Interventions
TYK-00540Drug
Take the specified dose (20mg or 30mg) orally twice a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
EnzalutamideDrug
Take orally, 160mg each time, once a day. Take orally with or without meals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience one or more adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
- Dose Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
- Maximum tolerated dose(MTD)Time frame: Within 28 days of the first dose
- Recommended Phase 2 Dose(RP2D)Time frame: Within 28 days of the last patient dosed in escalation stage
- Progression-free survival (rPFS)Time frame: Up to approximately 21 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.